A FAMILY GUIDE TO CARDIAC STEM CELL

THERAPY

Restore Flow; Restore Life

Interventional Cardiologist, over 25 years

• University of Georgia, BS

• Medical College of Georgia, M.D.

• Emory University, MBA.

• Vanderbilt University, Fellowship

Former Chief, Cardiac Sciences, Saint

Thomas Hospital, Nashville, Tennessee

American College of Cardiology, Trustee

American Heart Association, Former

President, Davison County Chapter

Howard T. Walpole, M.D.

Chief Medical Officer

Okyanos Heart Institute

More than 17,000 cardiac catheterizations

Howard T. Walpole, MD, MBA, FACC, FACAI

Chief Medical Officer

Leslie Miller, MD, FACC

Chief Science Officer, Okyanos Chair, Department of Cardiovascular Medicine, University of South Florida (USF) Director/CEO , USF Cardiovascular Clinical and Research Integrated Strategic Program World-renowned cardiologist, specifically in the areas of heart failure and transplant. Former Director, Cardiac Programs, Georgetown University School of Medicine, Georgetown University Hospital and Washington Hospital Center. Professor/Director, Cardiovascular Division, University of Minnesota.

Investigator in over 80 clinical trials including the use of adipose-derived stem and regenerative cells for the

treatment of cardiovascular disease.

Gretchen Dezelick, RN, BSN, CNOR, LHCRM

Director of Nursing

Over 25 years of nursing experience Certified Critical Care Nurse (CCRN) for more than 20 years Certified Peri-Operative Nurse (CNOR) Licensed Healthcare Risk Manager (LHCRM) Oversees care delivery & safety standards Represents nursing as a member of the senior leadership team

R.N., St. Joseph Hospital School of Nursing, Lancaster, PA BSN, Millersville State University, PA • American Association of

Critical Care Nurses • Association for Professionals in

Infection Control • Association of Peri-Operative

Registered Nurses • Florida Society of Healthcare

Risk Managers • American Society for

Healthcare Risk Management and Ambulatory Surgery Center Association.

Beyond Bypass Surgery

and Stents

Cell Therapy is the Next Generation

of Medicine

Okyanos Heart Institute

Medical Advisory Council

Eric Duckers, MD, PhD, FESC, FACC Erasmus University, Netherlands

Leslie Miller, MD, FACC University of South Florida

Farrell Mendelsohn, MD, FACC Center for Therapeutic Angiogenesis

Antonio Colombo, MD, FACC Columbus Hospital, San Raffaele Hospital

Evolution of Medicine

Cardiac stem cell therapy promises to be a new

phase in the treatment of coronary artery disease.

Past Future

Ischemic Diseases

Stroke

Cardiac

Diabetic Wounds

PVD

Radiation and Other Chronic Wounds

10

EU

FDA

EU Ahead of FDA with Comparable Safety

An English Speaking Country Recognizing

European Union (EU) Standards Convenient

to No-Option Patients

The Clinical Trials

Demonstrates Safety

and Better Quality of Life

PRECISE: Sustained Functional Benefit

Direct Injection Into Heart Muscle via Catheter

19

15.5 15.3

16.6

17.2 17.1

14.0

15.0

16.0

17.0

18.0

19.0

20.0

Baseline 6 Months 18 Months

Control

Cell

MV

O2 (

%)

p < 0.05 p < 0.05

Transplant

Okyanos Treatment

• Unique mixture of stem and regenerative cells. Trial evidence demonstrates that new blood vessels begin, and damaged heart muscle starts to heal itself.

• Boosts your body's ability to heal itself.

• Delivered via a catheter into the heart for optimal placement vs. a syringe passing through bloodstream.

• Derived from adipose tissue with 2400 times more stem cells than from bone marrow.

•Only EU Approved cell-processing device available today.

Adipose Derived Regenerative Cells

(ADRCs)

Celution™ is an approved European

Union

cell processing device.

“Fresh cells from adipose-tissue using the Celution™ system seems to have the most dramatic results of any cell therapy study I have seen in Chronic Ischemic Heart Disease.”

Francisco Fernandez-Aviles

MD, PhD

We Know..

Many Trial Patients Are Living Better & Longer than Expected

Cardiac Cell Therapy is Not (Yet) a “Cure”

Not dancing isn’t an option

Are You a Candidate?

When to consider cell therapy?

For continuing symptoms of heart failure despite bypass

surgery and/or stents, such as shortness of breath and

chest discomfort.

In patients with progressively worsening heart function with

or without symptoms.

For patients with evidence of inadequate cardiac blood flow.

A Partnership with Your Physician

Full Medical Screening

22 Minute Flight From Florida

to Freeport, Bahamas

Day

1

Visit Okyanos

Heart Institute Clinic

Day

2

Procedure Day

Day

3

Day of Rest

Day

4

Final Clinic Visit

& Return Home

Day

5

Determination For a Better

Quality of Life

With Cardiac Cell Therapy

U.S. cardiology team

quality of life

research

sterile, modern cath lab

easy access

short recovery a new standard of care